NewsRoom Articles - Page 93 of 154 - PsychedelicNewsWire (PNW)

MondayJun 28, 2021 1:30 pm

Researchers Find Naturally-Occurring Psychedelic Compound in Rat Brains

In the recent past, individuals from the different parts of the United States. as well as other countries in the world, have been traveling to South America to partake in psychedelic retreats. During these ceremonies, the individuals consume a brewed concoction made from ayahuasca, which has been used traditionally by indigenous communities in sacred religious ceremonies. The psychoactive brew induces hallucinogenic episodes that most of these individuals cite as life-changing. The main active ingredient that causes these psychedelic visions is known as DMT (dimethyltryptamine). A recent study conducted by researchers from the School of Medicine at the University of Michigan…

FridayJun 25, 2021 1:45 pm

Researchers Decry Scant Scientific Data on Psychedelic Microdosing

As psychedelics have become more popular and research has found the numerous benefits these substances potentially hold, microdosing has increased in popularity as well. For those who may not have come across the term, it refers to the practice of consuming low doses of psychedelic substances to improve an individual’s productivity, creativity or mood. While this practice has been heralded by some as effective, scientific evidence to back these claims is yet to be discovered. Now a team of researchers led by the Maastricht University and Imperial College London have investigated the practice and published its findings in the “Journal…

FridayJun 25, 2021 11:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both…

ThursdayJun 24, 2021 3:18 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant…

ThursdayJun 24, 2021 12:00 pm

Researchers Find That Mindfulness Meditation Boosts Psilocybin’s Beneficial Effects

In the recent past, numerous studies have focused on the clinical application of psychedelics, including LSD, ayahuasca and psilocybin, in treating anxiety and depression disorders being conducted. For example, University of Zurich researchers have demonstrated that mindfulness meditation can improve the positive long-term effects of an individual dose of psilocybin, which can be found in magic mushrooms. Psilocybin, which is the primary active ingredient in hallucinogenic mushrooms, and LSD are known to alter the perception of individuals who consume them as well as induce feelings of unity and bliss. These experiences of decreased self-focus and self-transcendence are similar to those…

WednesdayJun 23, 2021 1:45 pm

Proposed New York Legislation Seeks to Set Up Psychedelics Research Institute

At the start of this month, Linda Rosenthal, an Assemblywoman of the state of New York, introduced legislation that calls for the state to establish a research institute to study the therapeutic potential of psychedelic substances for individuals who are afflicted with a substance use disorder, including opioids and methamphetamine, among other substances. The institute would be managed and run by the state. Under the program, researchers would create an advisory board that would offer oversight of clinical trials and aid principal researchers at sites that lacked formal review board oversight as well as set up training programs for professionals…

TuesdayJun 22, 2021 9:45 am

Could Psychedelics Be Used to Understand Near-Death Experiences?

For decades now, researchers have been unable to decipher what exactly causes a near-death experience. While most scientific studies haven’t delved into the study of near-death experiences, researchers have discovered that the characteristics of these incidents remain constant 20 years after they occurred. This discovery offers researchers an opportunity to learn more about these incidents first-hand and call attention to the foundational characteristics of near-death experiences. A recent study found that near-death experiences were marked by the infamous tunnel of light, an out-of-body experience and a feeling of inner peace. Additionally, scientists are discovering that psychedelics may play a big…

MondayJun 21, 2021 1:15 pm

Researchers ID Psychedelic Analog That Counters Effects of Stress in Mice

New research conducted by researchers from the University of California-Santa Cruz has found that an individual dose of tabernanthalog (“TBG”) can repair neural circuits in the brain that are damaged by stress, enhance neuronal connection regrowth and remedy behavioral deficits such as cognitive inflexibility and anxiety that are caused by stress. TBG is a new compound that has a structure similar to ibogaine, a psychedelic drug. Prior studies have found that while ibogaine has the potential to treat addiction, it is also a powerful hallucinogen and can cause severe heart arrhythmias. However, unlike ibogaine, TBG lacks hallucinogenic and toxic effects.…

FridayJun 18, 2021 2:45 pm

Mike Tyson Asserts That Psilocybin Helped Change His Life

Towards the end of last year, Mike Tyson took on Ray Jones Jr. in a boxing match for the first time in more than a decade. In a pay-per-view exhibition, the two boxed, ending the eight-round fight 78 to 74 for Tyson. During an interview with Reuters, Mike Tyson, commonly known as Iron Mike, revealed that he had struggled with drug addiction in his life, asserting that the use of psilocybin helped him get back on his feet. He explained that once he was introduced to psilocybin mushrooms, his whole life changed, adding that the shrooms had helped him when…

ThursdayJun 17, 2021 2:45 pm

Scientists Study Psychopathology Through Social Dominance Lens

A report published recently in PLOS One revealed that the symptoms of mental health conditions affected how individuals responded to being placed in subordinate and dominant positions. The research stated that depressive and manic symptoms especially were linked to physiological and psychological responses to social dominance. CALM Program director Sheri Johnson, who is also a University of California psychology professor and the author of the study, stated that she had collaborated with her associates to review the literature on psychopathology and social dominance. Johnson explained that there were various studies suggesting how important social dominance was to various forms of…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000